Michael L Blute1, Nathan A Damaschke, David F Jarrard. 1. aDepartment of Urology, University of Wisconsin School of Medicine and Public Health bUniversity of Wisconsin Carbone Comprehensive Cancer Center cEnvironmental and Molecular Toxicology, University of Wisconsin, Madison, Wisconsin, USA.
Abstract
PURPOSE OF REVIEW: There is a major deficit in our ability to detect and predict the clinical behavior of prostate cancer (PCa). Epigenetic changes are associated with PCa development and progression. This review will focus on recent results in the clinical application of diagnostic and prognostic epigenetic markers. RECENT FINDINGS: The development of high throughput technology has seen an enormous increase in the discovery of new markers that encompass epigenetic changes including those in DNA methylation and histone modifications. Application of these findings to urine and other biofluids, but also cancer and noncancerous prostate tissue, has resulted in new biomarkers. There has been a recent commercial development of a DNA methylation-based assay for identifying PCa risk from normal biopsy tissue. Other biomarkers are currently in the validation phase and encompass combinations of multiple genes. SUMMARY: Epigenetic changes improve the specificity and sensitivity of PCa diagnosis and have the potential to help determine clinical prognosis. Additional studies will not only provide new and better biomarker candidates, but also have the potential to inform new therapeutic strategies given the reversibility of these processes.
PURPOSE OF REVIEW: There is a major deficit in our ability to detect and predict the clinical behavior of prostate cancer (PCa). Epigenetic changes are associated with PCa development and progression. This review will focus on recent results in the clinical application of diagnostic and prognostic epigenetic markers. RECENT FINDINGS: The development of high throughput technology has seen an enormous increase in the discovery of new markers that encompass epigenetic changes including those in DNA methylation and histone modifications. Application of these findings to urine and other biofluids, but also cancer and noncancerous prostate tissue, has resulted in new biomarkers. There has been a recent commercial development of a DNA methylation-based assay for identifying PCa risk from normal biopsy tissue. Other biomarkers are currently in the validation phase and encompass combinations of multiple genes. SUMMARY: Epigenetic changes improve the specificity and sensitivity of PCa diagnosis and have the potential to help determine clinical prognosis. Additional studies will not only provide new and better biomarker candidates, but also have the potential to inform new therapeutic strategies given the reversibility of these processes.
Authors: Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan Journal: Nature Date: 2002-10-10 Impact factor: 49.962
Authors: Joshi J Alumkal; Zhe Zhang; Elizabeth B Humphreys; Christina Bennett; Leslie A Mangold; Michael A Carducci; Alan W Partin; Elizabeth Garrett-Mayer; Angelo M DeMarzo; James G Herman Journal: Urology Date: 2008-04-02 Impact factor: 2.649
Authors: W H Lee; R A Morton; J I Epstein; J D Brooks; P A Campbell; G S Bova; W S Hsieh; W B Isaacs; W G Nelson Journal: Proc Natl Acad Sci U S A Date: 1994-11-22 Impact factor: 11.205
Authors: Kalipso Halkidou; Luke Gaughan; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson Journal: Prostate Date: 2004-05-01 Impact factor: 4.104
Authors: Bernard Kwabi-Addo; Woonbok Chung; Lanlan Shen; Michael Ittmann; Thomas Wheeler; Jaroslav Jelinek; Jean-Pierre J Issa Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: K D Sørensen; M O Abildgaard; C Haldrup; B P Ulhøi; H Kristensen; S Strand; C Parker; S Høyer; M Borre; T F Ørntoft Journal: Br J Cancer Date: 2013-01-15 Impact factor: 7.640
Authors: Vito Cucchiara; Joy C Yang; Vincenzo Mirone; Allen C Gao; Michael G Rosenfeld; Christopher P Evans Journal: Cancers (Basel) Date: 2017-01-16 Impact factor: 6.639